Adenosine deaminase activity and its isoenzyme pattern in patients with juvenile rheumatoid arthritis and systemic lupus erythematosus
Adenosine deaminase activity and its isoenzyme pattern in patients with juvenile rheumatoid arthritis and systemic lupus erythematosus
复制标题
DOI：
10.1007/s100670170005
复制
发表时间：
2001-01-01
影响因子：
3.4
通讯作者：
Catriu, D
中科院分区：
文献类型：
--
作者：
Hitoglou, S;Hatzistilianou, M;Catriu, D
腺苷脱氨酶（Adenosine deaminase， ADA）参与嘌呤代谢，在免疫系统机制中起重要作用。本研究旨在探讨类风湿关节炎（JRA）和系统性红斑狼疮（SLE）患儿不同病程血清和外周血淋巴细胞（pbl）中总ADA （tADA）及其同工酶ADA1和ADA2的活性。该研究包括34名风湿病患者，24名JRA患者和10名SLE患者，以及64名健康对照。通过Giusti方法和EHNA（红-9-（2-羟基-3-壬基）腺嘌呤）在疾病活动期（治疗前）以及缓解和复发期间的存在或不存在，在所有患者的血清和pbl中测量tADA活性及其同工酶。我们的数据显示，JRA和SLE患者血清和pbl中tADA活性的升高主要与血清中ADA2活性和pbl中ADA1活性的升高相关。它还与临床疾病活动和复发密切相关。JRA和SLE患者血清中tADA/ADA2活性和pbl中tADA/ADA1活性升高的原因仍有待阐明。然而，值得注意的是，测量tADA活性，以及血清中ADA2活性和pbl中tADA与ADA1活性，可以为评估JRA和SLE的病理生理提供生化方法。此外，tADA及其同工酶可以作为代表疾病活动性的替代参数。
Adenosine deaminase (ADA) is involved in purine metabolism and plays a significant role in the mechanisms of the immune system. The aim of this study was to investigate the activity of total ADA (tADA) and its isoenzymes ADA1 and ADA2 in serum and peripheral blood lymphocytes (PBLs) of children with juvenile rheumatoid arthritis (JRA) and systemic lupus erythematosus (SLE) in different phases of the diseases. The study comprised 34 patients with rheumatic disease, 24 with JRA and 10 with SLE, and 64 healthy controls. The tADA activity and its isoenzymes were measured in serum and PBLs of all patients by the method of Giusti and by the presence or absence of EHNA (erythro-9-(2-hydroxy-3-nonyl)adenine) during the active phase of the disease (before treatment), as well as during remission and relapse. Our data show that increased tADA activity in the serum and PBLs of patients with JRA and SLE is correlated mainly to increased levels of ADA2 activity in serum and ADA1 activity in PBLs. It also closely correlates with clinical disease activity and relapse. The cause of this increased tADA/ADA2 activity in serum and tADA/ADA1 activity in PBLs in JRA and SLE remains to be elucidated. Nevertheless, it may be noted that the measurement of tADA activity, together with ADA2 activity in serum and tADA with ADA1 activity in PBLs, could offer a biochemical approach to the assessment of the pathophysiology of JRA and SLE. Also, tADA and its isoenzymes could be used as alternative parameters representing disease activity.